Epidemiology aspects of the chronic HBV with HDV infection in Kazakhstan INTRODUCTION
The Scope of the Problem The prevalence of HBV and HBV-HDV has been unknown in Kazakhstan for a long time. According to the current statistics, 30 to 50 thousand people become infected every year in Kazakhstan. Kazakhstan is being considered as a high endemic country within the context of hepatitis B (more than 8%). With regard to the HDV prevalence, Kazakhstan has been referred as a medium endemic country. However, within the country the prevalence of the viral hepatitis is not homogenous and the statistical data are not completely reliable to the full extent. Implementation of the vaccination programs against hepatitis B for the prevention of the disease has resulted in the positive results. However, currently Hepatitis D is diagnosed in the late stages, which is therefore characterized by a rapidly progressive course of the disease, and low efficacy of the antiviral therapy. Hepatitis D can only occur in the presence of hepatitis B virus, the prevalence of the chronic form of the hepatitis B virus has been investigated. It was found that in the five-year period from 2012 to 2016 there has been a decrease in the incidence of HBV infection from 35.4 to 29.6 cases per 100,000 people. However, with regard to the HBV infection with HDV, a substantial increase in the disease prevalence has been determined. In particular, the HDV infection disease incidence has increased by 40% reaching a value of 0.39 cases per 100,000 people in 2016.The following endemic regions of the country with the highest disease prevalence has been determined: South Kazakhstan, West Kazakhstan, Zhambyl, Aktobe regions and the city of Astana. The highest disease prevalence of HBV infection has found to be the capital of the country with the value of 1.7 cases per 100,000 people. What's more, the disease prevalence in Astana has been consistently substantial in comparison to the other parts and regions of Kazakhstan. 
